Risk factors for hospitalisation due to respiratory syncytial virus infection in children receiving prophylactic palivizumab
Risk factors for hospitalisation due to respiratory syncytial virus infection in children receiving prophylactic palivizumab
复制标题
DOI：
10.1007/s00431-021-04216-7
复制
发表时间：
2021-08-21
影响因子：
3.6
通讯作者：
Takeda, Atsuhito
中科院分区：
文献类型：
--
作者：
Chida-Nagai, Ayako;Sato, Hiroki;Takeda, Atsuhito
呼吸道合胞病毒（RSV）是一种常见的病原体，在生命的最初几周和几个月内引起极其严重的呼吸道症状。在患有心肺疾病的婴儿中，RSV感染具有显著的临床影响。帕利珠单抗是一种针对RSV的人源化单克隆抗体，已被证明可显著降低诊断为RSV的高危婴儿的住院率。然而，尽管给予了帕利珠单抗，我们的机构仍发生了大量需要住院治疗或重症监护的RSV感染。本研究旨在分析与重度RSV相关的风险因素，尽管使用了帕利珠单抗。我们回顾性分析了688例在我院就诊或住院并接受帕利珠单抗治疗的患者的病历。37例（5.4%）患者尽管接受了帕利珠单抗治疗，但仍因RSV需要住院治疗。此外，这些患者中有31例（83.8%）需要在非季节住院接受帕利珠单抗注射。早产儿（
Respiratory syncytial virus (RSV) is a common pathogen that causes extremely severe respiratory symptoms in the first few weeks and months of life. In infants with cardiopulmonary diseases, RSV infections have a significant clinical impact. Palivizumab, a humanised monoclonal antibody for RSV, has been shown to significantly reduce the rate of hospitalisation of high-risk infants diagnosed with RSV. However, we have experienced a significant number of RSV infections in our institution that required hospitalisation or intensive care, despite the administration of palivizumab. This study aimed to analyse the risk factors associated with severe RSV despite the use of palivizumab. We retrospectively reviewed the medical records of 688 patients who visited or were admitted to our hospital and received palivizumab. Thirty-seven (5.4%) patients required hospitalisation for RSV, despite receiving palivizumab. In addition, 31 of these patients (83.8%) required hospitalisation out of season for palivizumab injection. Preterm birth (